Last reviewed · How we verify

African trypanosomiasis — Treatment Landscape & Competitive Intelligence

African trypanosomiasis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating African trypanosomiasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pentam PENTAMIDINE Fresenius Kabi Antiprotozoal Muscarinic acetylcholine receptor M4 1984-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in African trypanosomiasis
  2. Fresenius Kabi · 1 drug in African trypanosomiasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in African trypanosomiasis:

Cite this brief

Drug Landscape (2026). African trypanosomiasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/african-trypanosomiasis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing